Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nektar Therapeutics

24.76
-0.7700-3.02%
Post-market: 24.57-0.1900-0.77%16:58 EDT
Volume:994.01K
Turnover:24.57M
Market Cap:428.38M
PE:-2.60
High:26.43
Open:25.29
Low:23.81
Close:25.53
Loading ...

Nektar Therapeutics Price Target Maintained With a $6.50/Share by HC Wainwright & Co.

Dow Jones
·
13 Mar

William Blair Sticks to Their Hold Rating for Nektar Therapeutics (NKTR)

TIPRANKS
·
13 Mar

Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...

GuruFocus.com
·
13 Mar

Nektar Therapeutics expected to post a loss of 17 cents a share - Earnings Preview

Reuters
·
11 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
07 Mar

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets

PR Newswire
·
06 Mar

Nektar Therapeutics expected to post a loss of 17 cents a share - Earnings Preview

Reuters
·
04 Mar

Nektar Therapeutics expected to post a loss of 17 cents a share - Earnings Preview

Reuters
·
28 Feb

Nektar Therapeutics Announces Completion of Target Enrollment in Rezolve-Aa Phase 2B Clinical Trial of Rezpegaldesleukin in Patients With Severe-to-Very Severe Alopecia Areata

THOMSON REUTERS
·
26 Feb

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata

PR Newswire
·
26 Feb

Nektar Therapeutics Price Target Maintained With a $6.50/Share by HC Wainwright & Co.

Dow Jones
·
25 Feb

Buy Rating for Nektar Therapeutics: Strategic Collaboration with TrialNet Enhances Rezpeg’s Potential in Type 1 Diabetes

TIPRANKS
·
25 Feb

Analysts Have Conflicting Sentiments on These Healthcare Companies: Fresenius Medical Care (FMS), Herbalife (HLF) and Nektar Therapeutics (NKTR)

TIPRANKS
·
25 Feb

William Blair Reaffirms Their Hold Rating on Nektar Therapeutics (NKTR)

TIPRANKS
·
25 Feb

BRIEF-Nektar Announces Clinical Trial Agreement To Evaluate Rezpegaldesleukin

Reuters
·
24 Feb

Nektar Therapeutics Partners With TrialNet to Test Rezpegaldesleukin in Type 1 Diabetes

MT Newswires Live
·
24 Feb

Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients With New Onset Type 1 Diabetes Mellitus

THOMSON REUTERS
·
24 Feb

Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus

PR Newswire
·
24 Feb

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th

PR Newswire
·
24 Feb

B.Riley Financial Sticks to Their Buy Rating for Nektar Therapeutics (NKTR)

TIPRANKS
·
17 Feb